Department of Gastroenterology, Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University/Naval Medical University, Shanghai, China.
J Dig Dis. 2018 Nov;19(11):685-692. doi: 10.1111/1751-2980.12681.
Over the past decades, carbohydrate antigen 72-4 (CA72-4) was thought to be a tumor marker that was elevated in healthy individuals and patients with malignancies, including gastrointestinal (GI), ovarian, endometrial and lung malignancies. Furthermore, studies found that elevated serum CA72-4 might predict digestive tumors, especially gastric tumors, although there was still neither a sensitive nor specific tumor biomarker for gastric cancer (GC). This study aimed to evaluate the diagnostic accuracy of CA72-4 in predicting malignancies, especially GC.
Altogether 403 patients underwent a CA72-4 test after admission to the Department of Gastroenterology in Changhai Hospital, the Second Military Medical University, from 1 June 2015 to 31 October 2015. Their age and sex, main symptoms, and final diagnoses were summarized.
The positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio of CA72-4 for diagnosing GC were 31.58%, 79.17%, 1.70, and 0.97, respectively. In the receiver operating characteristic (ROC) curve analysis, the area under the ROC curve for discriminating between patients with GC and those without was 0.62.
Performing a CA72-4 test on its own is of little use for predicting malignances, especially GC, in patients with GI diseases.
在过去几十年中，糖类抗原 72-4（CA72-4）被认为是一种肿瘤标志物，在健康个体和恶性肿瘤患者中都会升高，包括胃肠道（GI）、卵巢、子宫内膜和肺癌。此外，研究发现，血清 CA72-4 升高可能预测消化道肿瘤，尤其是胃癌，尽管目前仍然没有一种敏感且特异的胃癌（GC）肿瘤标志物。本研究旨在评估 CA72-4 预测恶性肿瘤，特别是 GC 的诊断准确性。
2015 年 6 月 1 日至 10 月 31 日，共有 403 名患者在第二军医大学长海医院消化科就诊时接受了 CA72-4 检测。总结了他们的年龄、性别、主要症状和最终诊断。
CA72-4 诊断 GC 的阳性预测值、阴性预测值、阳性似然比和阴性似然比分别为 31.58%、79.17%、1.70 和 0.97。在接受者操作特征（ROC）曲线分析中，ROC 曲线区分 GC 患者和非 GC 患者的曲线下面积为 0.62。
单独进行 CA72-4 检测对于预测 GI 疾病患者的恶性肿瘤，特别是 GC，用处不大。
